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Abstract Although iron is essential in maintaining the
function of the central nervous system, it is a potent source
of reactive oxygen species. Excessive iron accumulation
occurs in many neurodegenerative diseases including
Alzheimer disease (AD), Parkinson’s disease, and Creutz-
feldt-Jakob disease, raising the possibility that oxidative
stress is intimately involved in the neurodegenerative
process. AD in particular is associated with accumulation
of numerous markers of oxidative stress; moreover,
oxidative stress has been shown to precede hallmark
neuropathological lesions early in the disease process, and
such lesions, once present, further accumulate iron, among
other markers of oxidative stress. In this review, we discuss
the role of iron in the progression of AD.
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Introduction
As the incidence of Alzheimer disease (AD) continues to
grow exponentially, progress in treating this disease con-
tinues to stagnate. Indeed, the leading effective therapy
available today targets cholinergic deficits, i.e., the result of
the disease process rather than the cause [1]. It is therefore
not surprising that therapy provides some symptomatic
relief only, and fails to alter the progression of the disease
or outcome. This overall paucity of treatment options has
provided impetus for potential treatment based on more
fundamental pathogenic concepts (e.g., amyloid cascade
hypothesis). Such approaches can be considered ‘‘lesion-
centered’’ as they have as their foundation a specific
hallmark lesion of AD (e.g., the senile plaque). The prob-
lem with the lesion-centered approach is that the hallmark
lesions of AD also occur in ‘‘normal aging,’’ and from the
standpoint of the neuropathology of AD, such lesions are
more likely a consequence of the disease process rather
than a cause [2]. Therefore, not surprisingly, progress in
AD treatment based on lesion-centered hypotheses con-
tinues in a Brownian-like motion. A fundamental reorga-
nization of the concepts related to etiology, pathogenesis,
and treatment of AD seems warranted (e.g., [3]). In
this review, we discuss the role of iron in AD pathogenesis
as a potential therapeutic target. The relevance of iron
in AD pathogenesis is suggested by data showing that: (1)
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iron is associated with oxidative stress and neurotoxicity;
(2) iron accumulation and oxidative stress precede
AD-associated lesions; and (3) iron is more readily
treatable. We will outline the role of iron in cellular
metabolism and neurodegenerative disease, and hopefully
provide a stimulus to generate new ideas and new ap-
proaches for treating this devastating condition.
Iron uptake, transport, and interaction with oxidative
products
Much like oxygen, iron is both an essential element for
cellular metabolism, and a source of cytotoxicity when
metabolism is dysfunctional. Indeed, excessive iron depo-
sition is observed in the central nervous system (CNS) in a
number of neurodegenerative diseases [4–6]. Iron uptake in
the brain is tightly controlled by transferrin receptor in the
endothelial cells and choroid plexus cells [7], or lactoferrin
receptor on neurons [8, 9]. For the export of iron from
neurons or non-neuronal cells, a brain-specific ceruloplas-
min is suggested to play a role [10, 11]. The importance of
ceruloplasmin in brain iron metabolism is highlighted by
the extreme accumulations of iron in patients with hered-
itary aceruloplasminemia (R. J. Castellani, G. Perry, and
M. A. Smith, unpublished observations).
The CNS uses its own transferrin whose expression is
regulated by a CNS specific promoter [12, 13]. Regarding
iron storage, ferritin binds and stores intracellular iron in
most CNS cells, keeping it in a redox-inactive state [14]. In
the pars compacta region of the substantia nigra, neuro-
melanin is known to play a part in iron storage [15]. To
maintain iron homeostasis, iron regulatory protein-1 and -2
(IRP1 and IRP2) regulate the expression of ferritin and
transferrin receptor post-transcriptionally through iron re-
sponse element (IRE) [16]. Iron is involved in various
cellular metabolisms, in particular, mitochondrial iron is
incorporated into heme and cytochromes [17]. For the
regulation of heme metabolism, heme oxygenase plays an
important role in the CNS [18, 19].
During the reduction of molecular oxygen, mitochondria
produce superoxide (O2
–). Enzymatic dismutation by
superoxide dismutase (SOD) in turn yields hydrogen per-
oxide (H2O2). Although O2
– and H2O2 by themselves are
relatively non-toxic, H2O2, which is freely permeable in
tissues, may lead to the production of the highly toxic
hydroxyl radical (OH) through a metal ion-catalyzed
Fenton reaction. This reaction is referred to as the super-
oxide-driven Fenton reaction or iron-catalyzed Haber-
Weiss reaction. Superoxide may also produce H2O2 non-
enzymatically. In its normal metabolic state, superoxide
favors the oxidation of Fe2+ to Fe3+. However, if the
intracellular concentration of superoxide is elevated, the
reaction favors the reduction of Fe3+ to Fe2+ and elabora-
tion of hydroxyl radicals.
In light of the high levels of oxygen consumption in the
CNS, the generation of a high level of reactive oxygen
species (ROS) is expected, as well as anti-oxidant defenses
commensurate with the free radical production. Under
normal situations, oxidative balance is maintained and free
radicals are detoxified. In disease, various modifications of
macromolecules such as sugars, lipids, proteins, and nu-
cleic acids, come into play, and it is now well established
that neurodegenerative diseases are associated with oxi-
dative imbalance and its sequelae. In the case of AD, many
lines of evidence now indicate that ROS induced by redox-
active metals including iron play a pivotal role in pathogenesis
[20–29]. In the following sections, we will discuss the sug-
gested mechanisms of iron in the neuropathology of AD.
Iron deposition and senile plaques
Iron accumulation in AD has been shown to be particularly
abundant in brain regions vulnerable to AD, including the
hippocampal formation and association cerebral cortices
[25]. At the microscopic level, it has been demonstrated to
accumulate in senile plaques in AD [30]. Further, increases
in iron accumulation and oxidative stress in AD brains are
related with changes in the concentration of soluble and
deposited amyloid-b protein. Experimentally, such meta-
bolic stresses including hypoglycemia, ischemia, and trau-
matic brain injury all augment amyloid-b protein precursor
formation and/or its mRNA [31–36]. Likewise, suppression
of mitochondrial energy metabolism alters the processing of
amyloid-b protein precursor to produce amyloidogenic
derivatives [37, 38] such that several studies have shown
that oxidative stress increases the production of amyloid-b
[39–41], and that H2O2 affects increased intracellular [39,
42] and secreted amyloid-b in neuronal cell lines [40]. On
the other hand, amyloid-b itself has been suggested to have
an ability to generate ROS, driving a potential positive
feedback loop whereby increased generation of ROS gen-
erates increased amyloid-b, and vice versa.
The three histidine residues of amyloid-b at position 6,
13, and 14 and one tyrosine residue at position 10, all
located in the hydrophilic N-terminal part of the peptide
[43, 44], behave as iron binding sites. The iron bound to
these sites has been shown to generate H2O2 by the Fenton
reaction [45–47]. Not only production of ROS but also
binding of iron to these residues induces amyloid-b
aggregation. Substitution of the histidine residue signifi-
cantly decreases the aggregation by Fe3+ [44]. Whether or
not the aggregation of amyloid-b and formation of senile
plaques is important in neurotoxicity [23, 26, 48–50], it
appears likely that extracellular iron is a major source of
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free radicals in the oxidatively damaged brain and that any
deleterious effects of amyloid-b are mediated by adventi-
tiously bound iron [51]. Notably, the redox potential of iron
is significantly attenuated by amyloid-b suggesting a neu-
roprotective chelating role for amyloid-b in disease path-
ogenesis [51, 52].
Besides the suggested direct involvement of iron, plaque
formation also induces an activation of microglia or reac-
tive astrocytes [53]. Activation of microglia and macro-
phages synthesize and secrete various cytokines such as
interleukin (IL)-1, IL-6, and IL-8. Chronic production of
these cytokines consequently causes activation of macro-
phages that produce large amounts of ROS [54]. Activated
microglia also release iron from ferritin in a superoxide
dependent fashion and result in lipid oxidation in vivo [55].
In fact, elevated levels of IL-1 and IL-6 in AD brain have
been reported [56]. Whether such microglial activation,
like amyloid-b activation [51], is mediated by iron is un-
clear.
Iron in neurofibrillary tangles
Neurofibrillary tangles (NFT) are another hallmark lesion
of AD and, interestingly, are another site of iron accumu-
lation. The presence of redox metals in NFT has been
shown to induce oxidative stress via H2O2 [57]. Although
NFT possibly act as a redox center, we previously dem-
onstrated that neurons, which lack NFT also contain oxi-
dative modifications [21], suggesting that oxidative stress
precedes the formation of NFT.
Among the macromolecules modified by ROS, RNA is
suggested as an early target of oxidative damage in AD
brain [26]. Using 8-hydroxyguanosine (8OHG) as a marker
of nucleic acid oxidation, oxidative damage can be found
within the neuronal perikaryal cytoplasm. Moreover,
8OHG essentially disappears after treatment with RNase.
Since 8OHG is formed by an attack of the hydroxyl radical,
and cannot permeate through the plasma membrane, 8OHG
must be produced within the cytoplasm in the vicinity of
RNA. It is possible, therefore, that transition metals such as
iron play a pivotal role in oxidation of RNA. In fact, studies
show RNA oxidization is increased in AD brain [58] and
subsequent protein translation is impaired [59].
Among the unanswered questions pertaining to the
role of iron in neurodegenerative disease is the precise
source of redox-active iron. Although mitochondria
possess various iron containing functional molecules,
such as heme, cytochrome, and aconitase, little 8OHG is
accumulated. On the other hand in situ hybridization and
ultrastructural observations reveal that mitochondrial
abnormalities exist in AD brain and many abnormal
mitochondria are targeted to lysosomes [60]. Since
lysosomes also accumulate iron, mitochondrial turnover
and lysosomal activity are a potential metabolic source of
iron within damaged cells.
Iron-containing compounds related to Alzheimer
disease
In spite of the importance of dysregulation of iron
homeostasis in AD and other neurodegenerative diseases,
relatively little is known about the resulting forms of iron,
which accumulate in the brain. Recently, studies have be-
gun to address this issue by using techniques such as
synchrotron X-ray absorption spectroscopy (XAS), elec-
tron tomographic imaging, and superconducting quantum
interference device (SQUID) magnetometry to character-
ize, locate and quantify specific iron compounds related to
AD, PD, and other neurodegenerative diseases.
The development of XAS as a technique for analyzing
and mapping iron and other metals related to tissue struc-
tures in avian brain tissue was first reported in 2005 [61].
Later that same year, Collingwood et al. [62, 63] demon-
strated the application of this technique to AD tissue sec-
tions. This work provided the first map of iron distribution
in AD tissue in which specific iron anomalies (areas of high
iron concentration) were not only located but characterized
with 5 lm spatial resolution. It was clear from this work
that the ‘‘normal’’ biological iron oxides, such as ferrihy-
drite and goethite-like hemosiderin, were not the only iron
compounds responsible for these anomalies. Biogenic
magnetite (a ferrimagnetic iron oxide—Fe3O4—which
contains both Fe2+ and Fe3+) was the primary component of
many of the regions of high iron concentration.
Biogenic magnetite has been reported in human brain
tissue from studies dating back to 1992 and is present as an
iron biomineral in many species [64–66]. However, in a
recent SQUID magnetometry study, Hautot et al. [67]
reported elevated levels of biogenic magnetite in female
AD subjects compared to both male and female controls.
The significance of these findings is that magnetite pro-
vides a potential source of ferrous iron, which is available
for oxidation and participation in Fenton chemistry (the
oxidation product of magnetite, maghemite—cFe2O3, has
also been found in AD tissue) and may potentiate free
radical formation in AD tissue via triplet state stabilization
[68–71].
These studies are beginning to highlight the importance
of understanding the specific biochemical pathways asso-
ciated with neurodegenerative diseases and the resulting
iron compounds, which are formed. This is particularly
important for the potential development of metal chelators
as therapeutic agents [72, 73] and this information may
also be exploited for non-invasive early detection of MRI
1642 Neurochem Res (2007) 32:1640–1645
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based on the effects of magnetic iron compounds on proton
relaxation rates as suggested several years ago [68, 74, 75].
Treatment potential
To date, treatment of AD with chelating agents such as
desferroxamine and clioquinol, a Cu2+ chelator, has been
met with limited success [76, 77]. The reasons for this may
be multifactorial. First, brain penetrant chelators are
essential [78]. Second, as oxidative injury begins at a rel-
atively early stage in disease, removal of iron by chelation
therapy years later may simply be a case of too little too
late. Early intervention is critical since the effects of oxi-
dative stress are both cumulative and on-going. Moreover,
iron is not the only source of free radicals within the brain.
Other heavy metals (e.g., Cu, Hg, and Pb), reactive nitro-
gen species, soluble mediators of inflammation, among
other sources, may also play a role. In this respect, a
multifaceted approach to treatment that targets early
events, prior to the onset of neuropathology, makes more
mechanistic sense. Targeting end-stage lesions likewise
appears all the more naı¨ve as understanding of AD and its
relationship with the aging process continues to improve
[48, 50, 79, 80].
Conclusion
There is no doubt that oxidative stress plays a pivotal role
in pathophysiology of AD and in regards to ROS genera-
tion, iron would be a key molecule responsible for the
formation of highly reactive hydroxyl radical. Both extra-
cellular and intracellular events related to ROS generation
have a great impact on the fate of neurons. Suggested by
the successful reports of metal chelation therapy for
improving neuronal function and cell viability, redox-ac-
tive iron is an attractive target for treatment of neurode-
generative disease [81, 82]. Further investigation of iron
will more clearly define the role of this redox-active ele-
ment in the pathophysiology of AD.
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